 Visit the TF Network Sites · Institutional Investor Center · Individual Investor Center |
| Download Plug-In |
| Real
Player 8 Basic Windows Media Player |
| Other Conference Calls |
| Other Feb 26 Calls Today's Calls |
| Call Details | |||
| POZEN Inc. Earnings Conference Call (Q4 2007) Tue, Feb 26, 2008, 11:00 am Eastern
| |||
| About POZEN Inc. (NasdaqGM:POZN) | |||
| POZEN, Inc., a development stage company, focuses on the development of products for the treatment of acute and chronic pain, and other pain-related conditions. The company is also exploring the development of product candidates in other pain-related therapeutic areas. Its principal product candidate, Trexima, is being developed in collaboration with GlaxoSmithKline for the acute treatment of migraine. Trexima is a proprietary single tablet containing sumatriptan succinate and naproxen sodium. The company entered into a collaboration and license agreement with AstraZeneca AB for the co-development and commercialization of proprietary fixed dose combinations of the proton pump inhibitor (PPI) esomeprazole magnesium, with the non-steroidal anti-inflammatory drug (NSAID) naproxen, in a single tablet. It has two product candidates in development that combine a PPI with an NSAID in a single tablet, which include PN 100, a combination of lansoprazole and naproxen; and PN 200, a combination of omeprazole and naproxen. These product candidates are intended to provide management of pain and inflammation associated with conditions, such as osteoarthritis, with fewer gastrointestinal complications compared to an NSAID taken alone. In addition, POZEN is exploring the development of product candidates containing lornoxicam, an NSAID to treat pain or other pain-related indications under a license agreement with Nycomed Danmark ApS; and a PPI with aspirin that is intended to reduce gastrointestinal ulcers and complications compared to an aspirin alone. The company was founded in 1996 and is headquartered in Chapel Hill, North Carolina. | |||
More Info: | |||
